Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Status:
Recruiting
Trial end date:
2025-12-21
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, open-label，single-center, phase II study, aiming to to
evaluate the surgical conversion feasibility of AK104 combined with apatinib, paclitaxel and
S-1 in unresectable stage IV G/GEJ cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital